
Carbapenem-resistant Klebsiella pneumoniae (CRKP) is propelled by mobile genetic elements that amplify and mobilize carbapenemases. We resolve an IS26-mediated inverted tandem duplication of blaNDM−4 on transferable IncFII(K)-repB(R1701) plasmids in two clinical isolates (L2388, L3835) from southern China, and document the co-location of blaNDM−4 and blaOXA−9 on the same plasmid. Hybrid long/short-read assemblies, junction-spanning PCR/Sanger validation, and conjugation assays show that pL2388-NDM-OXA (120,100 bp) and pL3835-NDM-OXA (127,486 bp) are conjugative and stable. In pL3835-NDM-OXA, two blaNDM−4 copies lie in opposing orientations within an IS26-rich resistance island, consistent with copy-number gain via IS26. Comparative plasmidomics identifies closely related IncFII(K)-repB(R1701) backbones and blaNDM−4 microvariants in datasets from southern China and Vietnam. Linking this duplication architecture to a transmissible backbone, we nominate backbone signatures, IS26 junctions, and duplication-specific read-coverage patterns as targets for sequencing-based surveillance and infection-control programs.
Sepsis-associated encephalopathy (SAE) represents one of the most severe complications of sepsis, characterized by diffuse neurological dysfunction. It significantly increases patient mortality and can lead to long-term neuropsychiatric sequelae, including cognitive deficits, anxiety, and depression, thereby imposing a substantial societal burden. Currently, the clinical diagnosis of SAE relies primarily on subjective assessment scales, and effective specific therapies are lacking, underscoring the need for further elucidation of its pathological mechanisms. Recent studies indicate that gut dysbiosis plays a pivotal role in the development of SAE. Consequently, probiotic-based microbiome intervention strategies offer a novel approach to SAE prevention and treatment by reshaping the gut microbiota, restoring beneficial metabolite levels, and inhibiting harmful immune cell migration. This review aims to systematically summarize the latest mechanistic studies on the gut microbiota-gut-brain axis in SAE. It focuses on evaluating the experimental evidence and potential clinical value of microbiological therapies, particularly probiotics, while outlining future challenges and translational research directions in this field. The goal is to provide a theoretical basis for developing precise intervention strategies for SAE.
Carbapenem-resistant Enterobacterales (CRE) can colonize the gastrointestinal tract and serve as a reservoir for infection and transmission. Live biotherapeutic products (LBPs) offer a potential strategy to suppress intestinal CRE colonization, but conventional plate-based screening may not reliably identify candidates that retain activity in a gut-like microbial ecosystem. This limitation hampers prioritization of therapeutically relevant LBP candidates and can lead to the advancement of false-positive candidates to animal testing. Here, we established a Robogut-based screening framework to evaluate anti-CRE candidate strains between primary plate-based screening and in vivo validation. Human fecal isolates were first screened against the CRE challenge strain Klebsiella pneumoniae PNUH40, and selected candidates were evaluated under Robogut-based in vitro CRE colonization conditions. Robogut-based screening distinguished candidates with activity retained under gut-like conditions from a plate-positive candidate that failed to retain activity, and the screening outcome was concordant with efficacy in a murine CRE colonization model. Microbial community analysis and targeted short-chain fatty acid quantification showed that Robogut culture established a fecal-derived microbial community and a metabolic environment characterized by acetate, propionate, and butyrate accumulation. These preliminary findings support the potential of Robogut-based screening as an intermediate step for prioritizing anti-CRE LBP candidates before animal validation.
Gastric cardia adenocarcinoma (GCA) shows marked geographic clustering, but microbial changes in its precursor lesions remain poorly defined. We characterized the mucosa-associated microbiome across normal gastric cardia mucosa, intestinal metaplasia (IM), and intraepithelial neoplasia (IEN), and examined its association with host epigenetic alterations. In this cross-sectional study, 16S rRNA gene sequencing was performed on 71 gastric cardia mucosal samples, including 17 Normal, 44 IM, and 10 IEN samples. Microbiome data were integrated with previously published DNA methylation and RNA-seq profiles from matched samples. Helicobacter pylori colonization was assessed by immunohistochemistry (IHC) in an independent expanded cohort with no overlapping participants. Alpha diversity did not differ significantly among histological groups in unadjusted analyses, whereas microbial community composition differed among histological groups (Bray–Curtis PERMANOVA R² = 0.115, P = 0.001) and remained associated with histology after adjustment for age and sex. Helicobacter was enriched in the combined IM/IEN group. In the independent IHC cohort, H. pylori positivity was highest in the IEN group (19 of 33 IEN cases). Neisseria had lower relative abundance in lesion samples, whereas the Greengenes2-assigned putative species Gemella morbillorum and Leptotrichia trevisanii were more abundant in IEN. An exploratory dysbiosis score was associated with the gene silencing score (Spearman rho = 0.61, P = 5.51 × 10⁻⁵), and the association remained nominally significant after adjustment for age, sex, and histological group. Because microbial and host features were selected and the scores were evaluated within the study datasets, these associations are susceptible to feature-selection bias. Gastric cardia precursor lesions show microbial remodeling that co-occurs with host epigenetic alterations. The score-based association is hypothesis-generating because of within-dataset feature selection and requires independent validation. Longitudinal sampling and functional studies are needed to establish temporal relationships and biological significance.
Blastocystis is a highly prevalent enteric protist whose clinical significance remains controversial. The organism exhibits substantial genetic diversity, yet molecular epidemiological data from clinical settings in Spain are still scarce. To determine the frequency and subtype diversity of Blastocystis in stool samples from patients with gastrointestinal symptoms who tested positive for the protist by routine diagnostic methods. This descriptive, prospective multicentre study was conducted between February 2016 and August 2019 across four tertiary hospitals located in three Spanish regions. Among 281 positive samples, 249 (88.6